CUE - キュ―・バイオファ―マ (Cue Biopharma Inc.)

CUEのニュース

   Cue Biopharma Earnings Perspective: Return On Capital Employed  2023/03/22 14:46:10 Benzinga
Cue Biopharma (NASDAQ: CUE ) brought in sales totaling $151 thousand during Q4 according to data provided by Benzinga Pro . However, earnings decreased 33.2%, resulting in a loss of $14.59 million. In Q3, Cue Biopharma brought in $68 thousand in sales but lost $10.96 million in earnings. What Is ROCE? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and … Full story available on Benzinga.com
   Cue Biopharma, Inc. (CUE) Q4 2022 Earnings Call Transcript  2023/03/22 03:00:23 Seeking Alpha
Cue Biopharma, Inc. (NASDAQ:NASDAQ:CUE) Q4 2022 Earnings Conference Call March 21, 2023 4:30 PM ETCompany ParticipantsDan Passeri - CEOMatteo Levisetti - Chief Medical OfficerKen Pienta -…
   Cue Biopharma GAAP EPS of -$0.37 misses by $0.06, revenue of $0.15M beats by $0.05M  2023/03/21 20:28:48 Seeking Alpha
Cue Biopharma press release (CUE): Q4 GAAP EPS of -$0.37 misses by $0.06.Revenue of $0.15M (-98.2% Y/Y) beats by $0.05M.Research and development expenses were $11.3…
   Cue Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights  2023/03/21 20:10:00 GlobeNewswire
BOSTON, March 21, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, today reported fourth quarter and full year 2022 financial results.
   Cue Biopharma''s Earnings Outlook  2023/03/20 15:01:43 Benzinga
Cue Biopharma (NASDAQ: CUE ) is set to give its latest quarterly earnings report on Tuesday, 2023-03-21. Here''s what investors need to know before the announcement. Analysts estimate that Cue Biopharma will report an earnings per share (EPS) of $-0.31. Cue Biopharma bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the … Full story available on Benzinga.com
   Cue Biopharma Earnings Perspective: Return On Capital Employed  2023/03/22 14:46:10 Benzinga
Cue Biopharma (NASDAQ: CUE ) brought in sales totaling $151 thousand during Q4 according to data provided by Benzinga Pro . However, earnings decreased 33.2%, resulting in a loss of $14.59 million. In Q3, Cue Biopharma brought in $68 thousand in sales but lost $10.96 million in earnings. What Is ROCE? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and … Full story available on Benzinga.com
   Cue Biopharma, Inc. (CUE) Q4 2022 Earnings Call Transcript  2023/03/22 03:00:23 Seeking Alpha
Cue Biopharma, Inc. (NASDAQ:NASDAQ:CUE) Q4 2022 Earnings Conference Call March 21, 2023 4:30 PM ETCompany ParticipantsDan Passeri - CEOMatteo Levisetti - Chief Medical OfficerKen Pienta -…
   Cue Biopharma GAAP EPS of -$0.37 misses by $0.06, revenue of $0.15M beats by $0.05M  2023/03/21 20:28:48 Seeking Alpha
Cue Biopharma press release (CUE): Q4 GAAP EPS of -$0.37 misses by $0.06.Revenue of $0.15M (-98.2% Y/Y) beats by $0.05M.Research and development expenses were $11.3…
   Cue Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights  2023/03/21 20:10:00 GlobeNewswire
BOSTON, March 21, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, today reported fourth quarter and full year 2022 financial results.
   Cue Biopharma''s Earnings Outlook  2023/03/20 15:01:43 Benzinga
Cue Biopharma (NASDAQ: CUE ) is set to give its latest quarterly earnings report on Tuesday, 2023-03-21. Here''s what investors need to know before the announcement. Analysts estimate that Cue Biopharma will report an earnings per share (EPS) of $-0.31. Cue Biopharma bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the … Full story available on Benzinga.com
   Cue Biopharma to Present at Two February 2023 Scientific Conferences  2023/02/01 13:00:00 GlobeNewswire
BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today that its President and Chief Scientific Officer, Anish Suri, Ph.D., will participate in two scientific conferences this February, the Immuno-Oncology 360 o Summit, taking place February 7-10 in New York, NY, and the Federation of American Societies for Experimental Biology (FASEB) Catalyst Conference , taking place virtually February 8-9, 2023.
   Cue biopharma names Matteo Levisetti as new Chief Medical Officer  2023/01/23 13:18:37 Seeking Alpha
Cue Biopharma (CUE) promotes its senior Vice President of clinical development, Matteo Levisetti, M.D., to Chief Medical Officer effective January 17, 2023
   Cue Biopharma Announces Chief Medical Officer Transition  2023/01/23 13:00:00 GlobeNewswire
BOSTON, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today that Matteo Levisetti, M.D., senior vice president (SVP) of clinical development at Cue Biopharma, has been promoted to Chief Medical Officer (CMO) effective January 17, 2023. Current acting CMO Kenneth Pienta, M.D., has transitioned from his current role and will serve as a clinical advisor to the company effective as of the same date.
   Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences  2022/11/22 13:00:00 GlobeNewswire
BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient’s body, announced today that it will take part in two fireside chats, the first at the Piper Sandler 34th Annual Healthcare Conference, to be held November 29-December 1 in New York, and the second at the JMP Securities Hematology & Oncology Summit, to be held virtually December 6-7.
   MDB Capital Holdings: Public Ventures LLC Completes First Public Company Financing as a Broker-Dealer for Cue Biopharma, Inc.  2022/11/17 14:08:00 Finanz Nachrichten
DALLAS, TX / ACCESSWIRE / November 17, 2022 / Public Ventures, LLC, a wholly owned subsidiary of MDB Capital Holdings, LLC, completed its first financing as a broker-dealer for Cue Biopharma, Inc. …

calendar